Lindahl advisor in the sale of Palette Life Sciences

The purchase price amounts to USD 600 million as well as an amount up to an additional USD 50 million, provided that a number of commercial targets are met. The transaction is subject to the customary conditions, including regulatory approvals, and is expected to be completed in the fourth quarter.

The Lindahl team in the transaction primarily consists of Michael Edquist and Alexander Tham, as the partners responsible, as well as Gunnar Mattsson, Fredrik Steen and Theo Biström.

For more information, see the official press release from Palette Life Sciences.

About Palette Life Sciences:

Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences’ products improve patient outcomes in urology and urogynecology, colorectal conditions, radiotherapy and interventional oncology. The company's portfolio of available products includes Barrigel®, Deflux®, Solesta® and Lidbree™. Palette Life Sciences is under the management of experienced health and medical care managers and has its headquarters in Stockholm, as well as offices in Santa Barbara (California) and Dallas (Texas) in the US, Sydney in Australia and Tokyo in Japan. Read more here.